Picture loading failed.

Pre-Made Ravulizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-472-1mg 1mg 3090
GMP-Bios-ab-472-10mg 10mg Inquiry
GMP-Bios-ab-472-100mg 100mg Inquiry
GMP-Bios-ab-472-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Ravulizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody
INN Name Ravulizumab
TargetCO5
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI Structure5i5k:HL:XY
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesAlexion Pharmaceuticals
Conditions ApprovedParoxysmal nocturnal haemoglobinuria
Conditions ActiveHaemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy
Conditions Discontinuedna
Development Techna